ArticleClinical cancer research : an official journal of the American Association for Cancer Research2020
Investigating PSMA-Targeted Radioligand Therapy Efficacy as a Function of Cellular PSMA Levels and Intratumoral PSMA Heterogeneity.
Article in Clinical cancer research : an official journal of the American Association for Cancer Research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 123 citations in OpenAlex.
- Association of Declining Prostate-specific Antigen Levels with Clinical Outcomes in Patients with Metastatic Castration-resistant Prostate Cancer Receiving [European urology · 2024Trial
- Safety Analyses of the Phase 3 VISION Trial of [European urology · 2024Trial
- The Prognostic Value of PosttreatmentJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2023Trial
- Efficacy and outcomes of [European journal of nuclear medicine and molecular imaging · 2026Article
- Emerging frontiers and challenges of artificial intelligence in PSMA-PET imaging: pioneering a new chapter in prostate cancer care.Japanese journal of radiology · 2026Review
- Genomic landscape and precision therapy in prostate cancer: current status and future directions.NPJ precision oncology · 2026Review
- Variable cellular and radiobiological effects of [Journal of experimental & clinical cancer research : CR · 2026Article
- Generation and characterization of novel high-affinity fully human antibodies targeting prostate-specific membrane antigen and prostatic acid phosphatase.Antibody therapeutics · 2025Article
- Review
- Effective Treatment of Disseminated Prostate Cancer Using CD46-Targeted 225Ac Therapy.Clinical cancer research : an official journal of the American Association for Cancer Research · 2025Article
- [Cancers · 2025Article
- [Role of prostate-specific membrane antigen positron emission tomography/computed tomography (PSMA-PET/CT) in staging].Urologie (Heidelberg, Germany) · 2025Review
- Design, preclinical evaluation, and first-in-human PET study of [European journal of nuclear medicine and molecular imaging · 2025Article
- Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer.Frontiers in oncology · 2025Review
- Novel astatine (European journal of nuclear medicine and molecular imaging · 2025Article
- Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.Nature reviews. Urology · 2025Review
- Aiming High: Prostate-specific Membrane Antigen Expression in Treatment-naïve Prostate Cancer.European urology · 2024Article
- Impact of cell geometry, cellular uptake region, and tumour morphology onEJNMMI physics · 2024Article
- Evaluating [European journal of nuclear medicine and molecular imaging · 2024Article
- Periprostatic adipose tissue inhibits tumor progression by secreting apoptotic factors: A natural barrier induced by the immune response during the early stages of prostate cancer.Oncology letters · 2024Article
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Commented on by
- Comment on
Authors and funding
12 authors at 1 institution in 1 country.
Funding
Abstract
purposeProstate-specific membrane antigen (PSMA) targeting radioligands deliver radiation to PSMA-expressing cells. However, the relationship between PSMA levels and intralesion heterogeneity of PSMA expression, and cytotoxic radiation by radioligand therapy (RLT) is unknown. Here we investigate RLT efficacy as function of PSMA levels/cell, and the fraction of PSMA EXPERIMENTAL
designRM1 cells expressing different levels of PSMA (PSMA
results
conclusionsIn the current models, both the degree of PSMA expression and the fraction of PSMA
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.